Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C, Moore SC, Davis C, Mohamed N, Nunag J, King C, Thompson AAR, Rowland-Jones SL, Docherty AB, Chalmers JD, Ho LP, Horsley A, Raman B, Poinasamy K, Marks M, Kon OM, Howard L, Wootton DG, Dunachie S, Quint JK, Evans RA, Wain LV, Fontanella S, de Silva TI, Ho A, Harrison E, Baillie JK, Semple MG, Brightling C, Thwaites RS, Turtle L, Openshaw PJM; ISARIC4C Investigators; PHOSP-COVID collaborative group. Liew F, et al. Among authors: brightling c. EBioMedicine. 2023 Jan;87:104402. doi: 10.1016/j.ebiom.2022.104402. Epub 2022 Dec 19. EBioMedicine. 2023. PMID: 36543718 Free PMC article.
Correction: The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium.
Daynes E, Baldwin M, Greening NJ, Yates T, Bishop NC, Mills G, Roberts M, Hamrouni M, Plekhanova T, Vogiatzis I, Echevarria C, Nathu R, McAuley HJC, Latimer L, Glennie J, Chambers F, Penfold R, Hume E, Megaritis D, Alexiou C, Potthof S, Hogg MJ, Haighton C, Nichol B, Leavy OC, Richardson M, Elneima O, Singapuri A, Sereno M, Saunders RM, Harris VC, Nolan CM, Bolton C, Houchen-Wolloff L, Harrison EM, Lone N, Quint J, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Ramen B, Wain LV, Brightling C, Man WD, Evans R, Singh SJ. Daynes E, et al. Among authors: brightling c. Trials. 2023 Feb 7;24(1):98. doi: 10.1186/s13063-023-07132-3. Trials. 2023. PMID: 36750957 Free PMC article. No abstract available.
Implementable Deep Learning for Multi-sequence Proton MRI Lung Segmentation: A Multi-center, Multi-vendor, and Multi-disease Study.
Astley JR, Biancardi AM, Hughes PJC, Marshall H, Collier GJ, Chan HF, Saunders LC, Smith LJ, Brook ML, Thompson R, Rowland-Jones S, Skeoch S, Bianchi SM, Hatton MQ, Rahman NM, Ho LP, Brightling CE, Wain LV, Singapuri A, Evans RA, Moss AJ, McCann GP, Neubauer S, Raman B; C-MORE/PHOSP-COVID Collaborative Group; Wild JM, Tahir BA. Astley JR, et al. Among authors: brightling ce. J Magn Reson Imaging. 2023 Oct;58(4):1030-1044. doi: 10.1002/jmri.28643. Epub 2023 Feb 17. J Magn Reson Imaging. 2023. PMID: 36799341 Free PMC article.
Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.
Taquet M, Skorniewska Z, Zetterberg H, Geddes JR, Mummery CJ, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Mansoori P, Greening NJ, Harrison EM, Docherty AB, Lone NI, Quint J, Greenhalf W, Wain LV, Brightling CE, Evans RE, Harrison PJ, Koychev I; PHOSP-COVID Study Collaborative Group. Taquet M, et al. Among authors: brightling ce. Brain Commun. 2023 Dec 27;6(1):fcad357. doi: 10.1093/braincomms/fcad357. eCollection 2024. Brain Commun. 2023. PMID: 38229877 Free PMC article.
Human Lung Mast Cells: Therapeutic Implications in Asthma.
Poto R, Criscuolo G, Marone G, Brightling CE, Varricchi G. Poto R, et al. Int J Mol Sci. 2022 Nov 21;23(22):14466. doi: 10.3390/ijms232214466. Int J Mol Sci. 2022. PMID: 36430941 Free PMC article. Review.
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.
Bousquet J, Melén E, Haahtela T, Koppelman GH, Togias A, Valenta R, Akdis CA, Czarlewski W, Rothenberg M, Valiulis A, Wickman M, Akdis M, Aguilar D, Bedbrook A, Bindslev-Jensen C, Bosnic-Anticevich S, Boulet LP, Brightling CE, Brussino L, Burte E, Bustamante M, Canonica GW, Cecchi L, Celedon JC, Chaves Loureiro C, Costa E, Cruz AA, Erhola M, Gemicioglu B, Fokkens WJ, Garcia-Aymerich J, Guerra S, Heinrich J, Ivancevich JC, Keil T, Klimek L, Kuna P, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Lemonnier N, Lodrup Carlsen KC, Louis R, Makela M, Makris M, Maurer M, Momas I, Morais-Almeida M, Mullol J, Naclerio RN, Nadeau K, Nadif R, Niedoszytko M, Okamoto Y, Ollert M, Papadopoulos NG, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Pfaar O, Regateiro FS, Ring J, Rouadi PW, Samolinski B, Sastre J, Savouré M, Scichilone N, Shamji MH, Sheikh A, Siroux V, Sousa-Pinto B, Standl M, Sunyer J, Taborda-Barata L, Toppila-Salmi S, Torres MJ, Tsiligianni I, Valovirta E, Vandenplas O, Ventura MT, Weiss S, Yorgancioglu A, Zhang L, Abdul Latiff AH, Aberer W, Agache I, Al-Ahmad M, Alobid I, Ansotegui IJ, Arshad SH, Asayag E, Barbara C, Baharudin A, Battur L, Bennoor KS, Berghea EC, Bergman… See abstract for full author list ➔ Bousquet J, et al. Among authors: brightling ce. Allergy. 2023 May;78(5):1169-1203. doi: 10.1111/all.15679. Epub 2023 Apr 10. Allergy. 2023. PMID: 36799120 Free article. Review.
Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study.
Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S. Brightling CE, et al. Ann Allergy Asthma Immunol. 2024 Apr 30:S1081-1206(24)00280-1. doi: 10.1016/j.anai.2024.04.031. Online ahead of print. Ann Allergy Asthma Immunol. 2024. PMID: 38697286 Free article.
Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic, Omalizumab, in Severe Asthma in Adults: Results of the SoMOSA Study.
Djukanović R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, Shapanis A, Skipp PJS, Postle A, Wheelock C, Dahlén SE, Sterk PJ, Brown T, Jackson DJ, Mansur A, Pavord I, Patel M, Brightling C, Siddiqui S, Bradding P, Sabroe I, Saralaya D, Chishimba L, Porter J, Robinson D, Fowler SJ, Howarth PH, Little L, Oliver T, Hill K, Stanton L, Allen A, Ellis D, Griffiths G, Harrison T, Akenroye A, Lasky-Su J, Heaney L, Chaudhuri R, Kurukulaaratchy R. Djukanović R, et al. Among authors: brightling c. Am J Respir Crit Care Med. 2024 Apr 18. doi: 10.1164/rccm.202310-1730OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 38635834
589 results